Share Options

Alliance Pharma PLC
28 April 2008


For immediate release                                             28 April 2008





                              ALLIANCE PHARMA PLC

                      ('Alliance Pharma' or 'the Company')


                                Share Options


Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces
that on 23 April 2008 it awarded the following share options over ordinary
shares of the Company to certain Directors.


Name             Position          Number of options   Exercise price        Date of       Percentage of
                                             awarded        per share        vesting     issued ordinary
                                                                                           share capital
Tony Booley      Sales & Marketing         1,110,000             8.5p  23 April 2011               0.68%
                          Director
Mark Tomlinson    Medical Director         1,115,000             8.5p  23 April 2011               0.69%
Richard Wright    Finance Director         1,113,000             8.5p  23 April 2011               0.69%




For further information:
Alliance Pharma plc                                         + 44 (0) 1249 466966

John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000

Mark Court / Rebecca Skye Dietrich

Numis Securities                                           + 44 (0) 20 7260 1000
David Poutney / Michael Meade




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products and continues to explore
opportunities to expand the range.


Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in the prevention of heart disease, in
Parkinson's disease, in nutrition, in nasal infections, in the treatment of
dermatological conditions, in childbirth and in the treatment of periodontitis
(a serious gum disease).  Alliance Pharma's sales are mainly prescription
driven.  Its products are distributed to hospitals directly and to
pharmaceutical wholesalers which service both hospital and retail pharmacies
with their prescription requirements.


Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.



                      This information is provided by RNS
            The company news service from the London Stock Exchange